Conference Proceedings
A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)
Michael Dickinson, Manali Kamdar, Brian JP Huntly, Carlos Fernandez De larrea, Raul Cordoba, Maria-Victoria Mateos, Adrian Alegre, Won-Seog Kim, Jin Seok Kim, Mark Dawson, Paul Sung-Hao Yeh, Faisal Basheer, Paolo Gallipoli, Aristeidis Chaidos, Alejandro Martin, Thierry Horner, James Winnberg, Lijoy K Mathew, Jeffrey Botbyl, Natalie Karpinich Show all
BLOOD | AMER SOC HEMATOLOGY | Published : 2018
Abstract
Abstract BACKGROUND: Patients with relapsed and/or refractory non-Hodgkin's lymphoma (NHL), especially those with aggressive lymphomas, have overall poor prognosis. Novel targets and therapies are under investigation. Molibresib (GSK525762) is a potent and specific inhibitor of the bromodomain and extraterminal domain (BET) family of proteins, the inhibition of which prevents transcriptional complex assembly and the subsequent expression of oncogenic drivers. Molibresib inhibits growth in NHL cell lines, both in vitro and in vivo. Study BET116183 was designed to evaluate the safety, tolerability, and preliminary efficacy of molibresib in relapsed and refractory hematologic mal..
View full abstract